Oxazolidinone antibiotics impair <i>ex vivo</i> megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets
Oxazolidinones (linezolid and tedizolid) adverse reactions include thrombocytopenia, the mechanism of which is still largely unknown. In cultured cells, oxazolidinones impair mitochondrial protein synthesis and oxidative metabolism. As mitochondrial activity is essential for megakaryocyte differentiation and maturation into platelets, we examined whether oxazolidinones impair these processes <i>ex vivo</i> and alter, in parallel, the activity of mitochondrial cytochrome <i>c</i>-oxidase (CYTOX; enzyme partly encoded by the mitochondrial genome) and cell morphology. Human CD34+ cells were isolated, incubated with cytokines (up to 14 days) and clinically relevant oxazolidinone concentrations or in control conditions, and used for (i) clonogenic assays [counting of megakaryocyte (CFU-Mk), granulocyte-monocyte (CFU-GM), burst-forming unit-erythroid (BFU-E) colonies]; (ii) the measure of the expression of megakaryocyte surface antigens (CD34 to CD41 and CD42); (iii) counting of proplatelets; (iv) the measurement of CYTOX activity; and (v) cell morphology (optic and electron microscopy). Oxazolidinones caused a significant decrease in BFU-E but not CFU-Mk or CFU-GM colonies. Yet, the megakaryocytic lineage was markedly affected, with a decreased differentiation of CD34+ into CD41+/CD42+ cells, an abolition of proplatelet formation and striking decrease in the numbers of large polylobulated nucleus megakaryocytes, with a complete loss of intracellular demarcation membrane system, disappearance of mitochondria, and suppression of CYTOX activity. These alterations were more marked in cells incubated with tedizolid than linezolid. These data suggest that oxazolidinones may induce thrombocytopenia by impairing megakaryocytic differentiation through mitochondrial dysfunction. Pharmacological interventions to prevent this toxicity might therefore be difficult as mitochondrial toxicity is most probably inherently linked to their antibacterial activity.
Authors
- Paul M. Tulkens (ORCID: https://orcid.org/0000-0002-7121-3623)
- Tamara Milošević (ORCID: https://orcid.org/0000-0003-1612-9450)
- Françoise Van Bambeke (ORCID: https://orcid.org/0000-0002-0052-7991)
- Stefan N. Constantinescu (ORCID: https://orcid.org/0000-0002-8599-2699)
- William Vainchenker (ORCID: https://orcid.org/0000-0003-4705-202X)
- Gaëlle Vertenoeil (ORCID: https://orcid.org/0000-0003-4129-882X)
Institutions
- Inserm (FR)
- Ludwig Cancer Research (BE)
- Institut Gustave Roussy (FR)
- University of Oxford (GB)
- Ludwig Cancer Research (GB)
- de Duve Institute (BE)
- Walloon Excellence in Lifesciences and Biotechnology (BE)
- UCLouvain (BE)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1128/aac.00533-24
- Citations
- 8
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.64
Funders
- Ludwig Institute for Cancer Research
- Institut National de la Santé et de la Recherche Médicale
- Fonds De La Recherche Scientifique - FNRS
- Ligue Contre le Cancer
- Stichting Tegen Kanker
- Institut National Du Cancer
- Novartis Pharma
- Université de Namur